News und Analysen
Is Summit Therapeutics a Millionaire Maker?
Multiple paths to immense wealth exist. A few lucky people win the lottery. Some start successful businesses. Others invest in stocks that deliver explosive gains.
Summit Therapeutics (NASDAQ: SMMT)
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly
It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and
2 Beaten-Down Stocks to Buy on the Dip
While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are
Should Dividend Stock Investors Buy AT&T Stock?
AT&T (NYSE: T) stock offers passive income investors a robust dividend yield and the chance for an increasing stock price.
*Stock prices used were the afternoon prices of March 19, 2025. The video
Who Is Nvidia's Biggest Rival? Jensen Huang Offered a Clue, and You May be Surprised by the Answer.
Nvidia (NASDAQ: NVDA) has built a dominant position in one of the highest-growth areas around: artificial intelligence (AI) chips. That has helped it generate enormous levels of revenue, for
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.25 per share
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.25 per share
EQS-News: Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer
EQS-News: Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer
EQS-Adhoc: Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
EQS-Adhoc: Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
EQS-News: Heidelberg Pharma to Receive Milestone Payment from Partner Huadong for Clinical Study with HDP-101 in China
EQS-News: Heidelberg Pharma to Receive Milestone Payment from Partner Huadong for Clinical Study with HDP-101 in China
EQS-News: Results of the 2026 Annual General Meeting for the 2024/25 financial year of BRAIN Biotech AG
EQS-News: Results of the 2026 Annual General Meeting for the 2024/25 financial year of BRAIN Biotech AG
EQS-News: Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
EQS-News: Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO™
Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO™
EQS-News: Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
EQS-News: Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
EQS-Adhoc: Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
EQS-Adhoc: Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
Lonza Completes its Transformation to a Pure-Play CDMO with Agreement to Divest Capsules & Health Ingredients
Lonza Completes its Transformation to a Pure-Play CDMO with Agreement to Divest Capsules & Health Ingredients
EQS-Adhoc: Formycon AG publishes preliminary figures for the 2025 fiscal year
EQS-Adhoc: Formycon AG publishes preliminary figures for the 2025 fiscal year
EQS-News: Immunic to Participate in Investor Conferences in March
EQS-News: Immunic to Participate in Investor Conferences in March
EQS-News: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
EQS-News: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
EQS-News: BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
EQS-News: BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
EQS-News: Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab)
EQS-News: Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab)
Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
EQS-News: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
EQS-News: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
EQS-Adhoc: BB Biotech AG publishes its 2025 annual report
EQS-Adhoc: BB Biotech AG publishes its 2025 annual report
EQS-News: Annual Report 2025: BB Biotech delivers strong performance and portfolio value realization
EQS-News: Annual Report 2025: BB Biotech delivers strong performance and portfolio value realization
EQS-News: Immunic Announces Closing of Oversubscribed Private Placement Financing
EQS-News: Immunic Announces Closing of Oversubscribed Private Placement Financing